广西地区非小细胞肺癌中K-ras基因点突变的研究

BACKGROUND AND OBJECTIVE: Recent studies indicated that non-small cell lung cancer (NSCLC) patients with mutant K-ras were resistant to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). The aim of this study is to explore the relationship between the mutation of K-ras gene and NSCLC in Guangxi by detecting the point mutations in codon 12, 13 and 61 of K-ras gene in NSCLC. METHODS: The point mutations in codon 12, 13 and 61 of K-ras gene were detected by single-strand conformation polymorphism (SSCP) analysis of polymerase chain reaction (PCR) products and DNA sequencing analysis in 105 cases of NSCLC tissues and 30 cases of adjacent normal tissues. RESULTS: No point mutation in codon 12, 13 and 61 of K-ras gene was found in 105 cases of NSCLC tissues and 30 cases of adjacent normal tissues. In this study, the mutation frequency of K-ras gene in NSCLC was 0 (0/105). CONCLUSION: The high proportion of K-ras gene in wild-type indicates that patients with NSCLC in Guangxi could take more benefits from the therapy with EGFR-TKIs.